Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis

References

• ForouzanfarMHForemanKJDelossantosAMBreast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysisLancet201137898011461148421924486
   PubMed Web of Science ®Google Scholar
• PratAPerouCMDeconstructing the molecular portraits of breast cancerMol Oncol20115152321147047
   PubMed Web of Science ®Google Scholar
• SørlieTPerouCMTibshiraniRGene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProc Natl Acad Sci U S A20019819108691087411553815
   PubMed Web of Science ®Google Scholar
• ParkerJSMullinsMCheangMCSupervised risk predictor of breast cancer based on intrinsic subtypesJ Clin Oncol20092781160116719204204
   PubMed Web of Science ®Google Scholar
• BastienRRRodríguez-LescureÁEbbertMTPAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markersBMC Med Genomics201254423035882
   PubMed Web of Science ®Google Scholar
• VoducKDCheangMCTyldesleySGelmonKNielsenTOKenneckeHBreast cancer subtypes and the risk of local and regional relapseJ Clin Oncol201028101684169120194857
   PubMed Web of Science ®Google Scholar
• CoatesASWinerEPGoldhirschAAmerican Society of Clinical Oncology; College of American PathologistsTailoring therapies— improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Ann Oncol20152681533154625939896
   PubMed Web of Science ®Google Scholar
• FoulkesWDSmithIEReis-FilhoJSTriple-Negative Breast CancerN Engl J Med2010363201938194821067385
   PubMed Web of Science ®Google Scholar
• HammondMEHayesDFDowsettMAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerArch Pathol Lab Med2010134690792220524868
   PubMed Web of Science ®Google Scholar
• WolffACHammondMESchwartzJNAmerican Society of Clinical Oncology; College of American PathologistsAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerJ Clin Oncol200725111814517159189
   PubMed Web of Science ®Google Scholar
• IrvinWJJrCareyLAWhat is triple-negative breast cancer?Eur J Cancer200844182799280519008097
   PubMed Web of Science ®Google Scholar
• LinNUVanderplasAHughesMEClinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer NetworkCancer2012118225463547222544643
   PubMed Web of Science ®Google Scholar
• SmidMWangYZhangYSubtypes of breast cancer show preferential site of relapseCancer Res20086893108311418451135
   PubMed Web of Science ®Google Scholar
• DentRTrudeauMPritchardKITriple-negative breast cancer: clinical features and patterns of recurrenceClin Cancer Res20071315 Pt 14429443417671126
   PubMed Web of Science ®Google Scholar
• KaplanHGMalmgrenJAAtwoodMT1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapyBreast J200915545446019671105
   PubMed Web of Science ®Google Scholar
• PodoFBuydensLMDeganiHFEMME ConsortiumTriple-negative breast cancer: present challenges and new perspectivesMol Oncol20104320922920537966
   PubMed Web of Science ®Google Scholar
• AlvarezRHValeroVHortobagyiGNEmerging targeted therapies for breast cancerJ Clin Oncol201028203366337920530283
   PubMed Web of Science ®Google Scholar
• SenkusEKyriakidesSPenault-LlorcaFESMO Guidelines Working GroupPrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201324Suppl 6vi7vi2323970019
   PubMed Web of Science ®Google Scholar
• NCCNNCCN guidelinesBreast cancer, version 32017 Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdfAccessed March 2, 2017
   Google Scholar
• HafftyBGYangQReissMLocoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancerJ Clin Oncol200624365652565717116942
   PubMed Web of Science ®Google Scholar
• Trendell-SmithNJPestonDShoushaSAdenoid cystic carcinoma of the breast: a tumour commonly devoid of oestrogen receptors and related proteinsHistopathology199935324124810469216
   PubMed Web of Science ®Google Scholar
• LehmannBDBauerJAChenXIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJ Clin Invest201112172750276721633166
   PubMed Web of Science ®Google Scholar
• PusztaiLGene expression profiling of breast cancerBreast Cancer Res200911Suppl(3)S1120030862
   PubMed Web of Science ®Google Scholar
• BertucciFFinettiPCerveraNHow basal are triple-negative breast cancers?Int J Cancer2008123123624018398844
   PubMed Web of Science ®Google Scholar
• BadveSDabbsDJSchnittSJBasal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologistsMod Pathol201124215716721076464
   PubMed Web of Science ®Google Scholar
• ChooJRNielsenTOBiomarkers for Basal-like Breast CancerCancers (Basel)2010221040106524281106
   PubMedGoogle Scholar
• RakhaEAEl-SayedMEGreenARLeeAHRobertsonJFEllisIOPrognostic markers in triple-negative breast cancerCancer20071091253217146782
   PubMed Web of Science ®Google Scholar
• EdgeSBComptonCCThe American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNMAnn Surg Oncol20101761471147420180029
   PubMed Web of Science ®Google Scholar
• ElstonCWEllisIOPathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-upHistopathology19911954034101757079
   PubMed Web of Science ®Google Scholar
• RosenPPSaigoPEBraunDWJrWeathersEDePaloAPredictors of recurrence in stage I (T1N0M0) breast carcinomaAnn Surg1981193115257458446
   PubMed Web of Science ®Google Scholar
• BradburnMJClarkTGLoveSBAltmanDGSurvival analysis Part III: multivariate data analysis -- choosing a model and assessing its adequacy and fitBr J Cancer200389460561112915864
   PubMed Web of Science ®Google Scholar
• KashiwagiSYashiroMTakashimaTSignificance of E-cadherin expression in triple-negative breast cancerBr J Cancer2010103224925520551954
   PubMed Web of Science ®Google Scholar
• WonJRGaoDChowCA survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standardMod Pathol201326111438145023702728
   PubMed Web of Science ®Google Scholar
• NielsenTOHsuFDJensenKImmunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinomaClin Cancer Res200410165367537415328174
   PubMed Web of Science ®Google Scholar
• AdamsSGrayRJDemariaSPrognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199J Clin Oncol201432272959296625071121
   PubMed Web of Science ®Google Scholar
• WangCPanBZhuHPrognostic value of androgen receptor in triple negative breast cancer: A meta-analysisOncotarget2016729464824649127374089
   PubMedGoogle Scholar
• UrruticoecheaASmithIEDowsettMProliferation marker Ki-67 in early breast cancerJ Clin Oncol200523287212722016192605
   PubMed Web of Science ®Google Scholar
• de AzambujaECardosoFde CastroGJrKi-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patientsBr J Cancer200796101504151317453008
   PubMed Web of Science ®Google Scholar
• WangWWuJZhangPPrognostic and predictive value of Ki-67 in triple-negative breast cancerOncotarget2016721310793108727145269
   PubMedGoogle Scholar
• YardenYSliwkowskiMXUntangling the ErbB signalling networkNat Rev Mol Cell Biol20012212713711252954
   PubMed Web of Science ®Google Scholar
• SiziopikouKPArigaRProussaloglouKEGattusoPCobleighMThe challenging estrogen receptor-negative/progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy?Breast J200612436036216848847
   PubMed Web of Science ®Google Scholar
• VialeGRotmenszNMaisonneuvePInvasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivityBreast Cancer Res Treat2009116231732818839307
   PubMed Web of Science ®Google Scholar
• AndrewsJLKimACHensJRThe role and function of cadherins in the mammary glandBreast Cancer Res201214120322315958
   PubMed Web of Science ®Google Scholar
• GumbinerBMRegulation of cadherin-mediated adhesion in morphogenesisNat Rev Mol Cell Biol20056862263416025097
   PubMed Web of Science ®Google Scholar
• BaranwalSAlahariSKMolecular mechanisms controlling E-cadherin expression in breast cancerBiochem Biophys Res Commun2009384161119379710
   PubMed Web of Science ®Google Scholar
• Gould RothbergBEBrackenMBE-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysisBreast Cancer Res Treat2006100213914816791476
   PubMed Web of Science ®Google Scholar
• ThieryJPEpithelial–mesenchymal transitions in tumour progressionNat Rev Cancer20022644245412189386
   PubMed Web of Science ®Google Scholar
• PratAParkerJSKarginovaOPhenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancerBreast Cancer Res2010125R6820813035
   PubMed Web of Science ®Google Scholar
• Mahler-AraujoBSavageKParrySReis-FilhoJSReduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotypeJ Clin Pathol200861561562018156431
   PubMed Web of Science ®Google Scholar
• CheangMCVoducDBajdikCBasal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotypeClin Cancer Res20081451368137618316557
   PubMed Web of Science ®Google Scholar
• PintensSNevenPDrijkoningenMTriple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1J Clin Pathol200962762462819561231
   PubMed Web of Science ®Google Scholar
• RaoCShettyJPrasadKHImmunohistochemical profile and morphology in triple - negative breast cancersJ Clin Diagn Res2013771361136523998066
   PubMedGoogle Scholar
• SuttonLMHanJSMolbergKHIntratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinomaAm J Clin Pathol2010134578278720959661
   PubMed Web of Science ®Google Scholar
• KutomiGOhmuraTSuzukiYHirataKHistory and future of surgical treatmentNihon Rinsho201270Suppl 71317 Japanese
   Google Scholar
• InancMOzkanMKaracaHCytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancerMed Oncol201431180124326984
   PubMed Web of Science ®Google Scholar
• AdamoBRicciardiGRRIeniAThe prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancerOncotarget2017844769747698629100362
   PubMedGoogle Scholar
• LacroixMToillonRALeclercqGp53 and breast cancer, an updateEndocr Relat Cancer200613229332516728565
   PubMed Web of Science ®Google Scholar
• TsudaHHirohashiSAssociation among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancerInt J Cancer19945744985037910151
   PubMed Web of Science ®Google Scholar
• SoussiTBéroudCAssessing TP53 status in human tumours to evaluate clinical outcomeNat Rev Cancer20011323324011902578
   PubMed Web of Science ®Google Scholar
• OlivierMLangerødACarrieriPThe clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancerClin Cancer Res20061241157116716489069
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• GajdosCTartterPIBleiweissIJLymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancersAnn Surg1999230569269610561094
   PubMed Web of Science ®Google Scholar
• DingLEllisMJLiSGenome remodelling in a basal-like breast cancer metastasis and xenograftNature20104647291999100520393555
   PubMed Web of Science ®Google Scholar
• PanYYuanYLiuGWeiYP53 and Ki-67 as prognostic markers in triple-negative breast cancer patientsPLoS One2017122e017232428235003
   PubMed Web of Science ®Google Scholar
• BiganzoliECoradiniDAmbrogiFp53 status identifies two subgroups of triple-negative breast cancers with distinct biological featuresJpn J Clin Oncol201141217217921199790
   PubMed Web of Science ®Google Scholar
• CoatesASMillarEKO’TooleSAPrognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IXBreast Cancer Res2012146R14323127292
   PubMed Web of Science ®Google Scholar
• ChaeBJBaeJSLeeAp53 as a specific prognostic factor in triple-negative breast cancerJpn J Clin Oncol200939421722419304743
   PubMed Web of Science ®Google Scholar
• BasuAHaldarSThe relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell deathMol Hum Reprod1998412109911099872359
   PubMed Web of Science ®Google Scholar
• TsujimotoYFingerLRYunisJNowellPCCroceCMCloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocationScience19842264678109710996093263
   PubMed Web of Science ®Google Scholar
• LeungLKWangTTParadoxical regulation of Bcl-2 family proteins by 17beta-oestradiol in human breast cancer cells MCF-7Br J Cancer199981338739210507761
   PubMed Web of Science ®Google Scholar
• DawsonSJMakretsovNBlowsFMBCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy receivedBr J Cancer2010103566867520664598
   PubMed Web of Science ®Google Scholar
• Abdel-FatahTMPerryCDickinsonPBcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settingsAnn Oncol201324112801280723908177
   PubMed Web of Science ®Google Scholar
• TawfikKKimlerBFDavisMKFanFTawfikOPrognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between “triple-negative” and non-”triple-negative” tumorsHum Pathol2012431233021777944
   PubMed Web of Science ®Google Scholar
• NielsenKVEjlertsenBMøllerSThe value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89DActa Oncol200847472573418465341
   PubMed Web of Science ®Google Scholar
• ArriolaERodriguez-PinillaSMLambrosMBTopoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancerBreast Cancer Res Treat2007106218118917260090
   PubMed Web of Science ®Google Scholar
• MrklićIPogorelićZĆapkunVTomićSExpression of topoisomerase II-α in triple negative breast cancerAppl Immunohistochem Mol Morphol201422318218723702653
   PubMedGoogle Scholar
• CalhounBCLaniganCRubinBMrazeckKCRosaCBarnesMTOP2A-based prognostication in triple negative breast cancer and correlation with basal phenotypeJ Clin Oncol201533Suppl 15109825732171
   PubMed Web of Science ®Google Scholar
• RaoAMHatcherJFDempseyRJLipid alterations in transient fore-brain ischemia: possible new mechanisms of CDP-choline neuroprotectionJ Neurochem20007562528253511080206
   PubMed Web of Science ®Google Scholar
• DuboisRNAbramsonSBCroffordLCyclooxygenase in biology and diseaseFASEB J19981212106310739737710
   PubMed Web of Science ®Google Scholar
• CostaCSoaresRReis-FilhoJSLeitãoDAmendoeiraISchmittFCCyclooxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancerJ Clin Pathol200255642943412037025
   PubMed Web of Science ®Google Scholar
• SubbaramaiahKNortonLGeraldWDannenbergAJCyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3J Biol Chem200227721186491865711901151
   PubMed Web of Science ®Google Scholar
• WittonCJHaweSJCookeTGBartlettJMCyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancerHistopathology2004451475415228443
   PubMed Web of Science ®Google Scholar
• KlapperLNGlatheSVaismanNThe ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factorsProc Natl Acad Sci U S A19999694995500010220407
   PubMed Web of Science ®Google Scholar
• KaramouzisMVDalagiorgouGGeorgopoulouUNonniAKontosMPapavassiliouAGHER-3 targeting alters the dimerization pattern of ErbB protein family members in breast carcinomasOncotarget2016755576559726716646
   PubMedGoogle Scholar
• WittonCJReevesJRGoingJJCookeTGBartlettJMExpression of the HER1-4 family of receptor tyrosine kinases in breast cancerJ Pathol2003200329029712845624
   PubMed Web of Science ®Google Scholar
• TorrisiRRotmenszNBagnardiVHER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17Eur J Cancer200743162339234417855075
   PubMed Web of Science ®Google Scholar
• ChiaSNorrisBSpeersCHuman epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancersJ Clin Oncol200826355697570419001334
   PubMed Web of Science ®Google Scholar
• SchmidtGMeyberg-SolomayerGGerlingerCIdentification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expressionArch Gynecol Obstet201429061221122925012601
   PubMed Web of Science ®Google Scholar
• IlieSMDesauwCHebbarMHER2 based expression subpopulations in TNBC: pathological aspects and clinical significanceAnn Oncol201627suppl(6)vi15vi42
   Google Scholar
• ThikeAAIqbalJCheokPYTriple negative breast cancer: outcome correlation with immunohistochemical detection of basal markersAm J Surg Pathol201034795696420495445
   PubMed Web of Science ®Google Scholar
• RheeJHanSWOhDYThe clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancerBMC Cancer2008830718947390
   PubMed Web of Science ®Google Scholar
• KashiwagiSYashiroMTakashimaTAdvantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67Breast Cancer Res2011136R12222126395
   PubMed Web of Science ®Google Scholar
• MiyashitaMIshidaTIshidaKHistopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidatesVirchows Arch20114581657221104095
   PubMed Web of Science ®Google Scholar